<DOC>
	<DOCNO>NCT03078075</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomized clinical trial evaluate efficacy extended-release naltrexone plus bupropion combination pharmacotherapy methamphetamine use disorder . Participants randomly assign active medication combination ( AMC ) group match placebo group receive medication course 12 week . Follow-ups occur week 13 16 .</brief_summary>
	<brief_title>Accelerated Development Additive Pharmacotherapy Treatment ( ADAPT-2 ) Methamphetamine Use Disorder</brief_title>
	<detailed_description>There 370 adult moderate severe methamphetamine use disorder randomize multi-site study . Eligibility determine maximum 21 day screen period . After screen complete eligibility confirm , include successful administration naloxone challenge , participant begin 12 week medication phase trial . Participants randomize either 1 ) AMC arm receive injection extend release naltrexone ( XR-NTX ; Vivitrol® ) plus once-daily oral extended-release bupropion tablet ( BUP-XL ) 2 ) match placebo ( PLB ) arm receive injection placebo ( iPLB ) plus once-daily oral placebo ( oPLB ) tablet . During course study , participant may switch another arm , determine priori adaptive aspect study design . Participants appear respond well original treatment assignment switch . Overall , approximately 50 % participant receive AMC . Injections administer every three week , week 1 , 4 , 7 , 10 . Take-home oral study medication ( BUP-XL oPLB ) dispense weekly dose non-clinic day . Participants ask attend clinic twice weekly observed oral medication dosing , assessment , collection urine sample , once-weekly medical management . On non-clinic day , participant participate smartphone app-based medication adherence activity . Participants ask complete assessment indicate schedule assessment . Following 12 week medication phase , participant complete follow-up phase , include medication taper post-medication phase follow-up visit week 13 16 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>18 65 year old ; Interested reducing/stopping methamphetamine use ; Speak English ; Agree use acceptable birth control ( applicable ) ; Be opioidfree randomization ; Willing comply study procedure medication instruction ; Agree use cell phone ( similar study device ) take videos medication dosing . Medical psychiatric condition would make participation unsafe ; Recently participate study pharmacological behavioral treatment methamphetamine use disorder ; Recently take investigational drug ; Prescribed take naltrexone bupropion ≤ 30 day consent ; Current plan extend absence study period ( e.g. , jail , surgery , pending legal action ) ; Currently pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>Methamphetamine Use Disorder</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Bupropion</keyword>
	<keyword>Vivitrol®</keyword>
</DOC>